Monday, June 5, 2023, Chicago, Illinois, 7:00 PM – 9:30 PM Central Time (8:00 PM – 10:30 PM Eastern Time)

Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Breast Cancer

A CME Hybrid Symposium Held in Conjunction with the 2023 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:30 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Komal Jhaveri, MD
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine
Weill Cornell College of Medicine
New York, New York

Kevin Kalinsky, MD, MS
Associate Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Glenn Family Breast Center
Director, Breast Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Ian E Krop, MD, PhD
Associate Cancer Center Director
for Clinical Research
Director, Clinical Trials Office
Yale Cancer Center
New Haven, Connecticut


Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Professor Peter Schmid, FRCP, MD, PhD
Lead, Centre of Experimental Cancer Medicine
Barts Cancer Institute
London, United Kingdom

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Lilly, Merck, Natera Inc, Puma Biotechnology Inc, Seagen Inc, Stemline Therapeutics Inc, and TerSera Therapeutics LLC.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:30 PM — Educational Meeting

MODULE 1: Long-Term Management of HER2-Positive Breast Cancer — Dr Krop

  • Key clinical factors in the selection of neoadjuvant and adjuvant systemic therapy for HER2-positive localized breast cancer
  • Published clinical research findings with postadjuvant neratinib for HER2-positive localized breast cancer; improved rates of CNS recurrence with extended adjuvant neratinib
  • Dose escalation and other available approaches to mitigate neratinib-associated gastrointestinal toxicities
  • Clinical factors affecting the selection and sequencing of therapy for HER2-positive metastatic breast cancer (mBC)
  • Key efficacy and safety findings from the Phase III DESTINY-Breast03 trial evaluating trastuzumab deruxtecan (T-DXd) versus T-DM1 for HER2-positive mBC previously treated with trastuzumab and a taxane; implications for sequencing of therapy
  • Published data sets (eg, from the HER2CLIMB, DESTINY-Breast01, DESTINY-Breast02 and NALA trials) evaluating tucatinib/trastuzumab/capecitabine, T-DXd and neratinib/capecitabine, respectively, for multiregimen-relapsed HER2-positive mBC
  • Observed CNS activity with tucatinib/trastuzumab/capecitabine, T-DXd and neratinib/capecitabine in the pivotal studies leading to their approvals and other recent research efforts, such as TUXEDO-1 and DEBBRAH

MODULE 2: Optimizing the Management of ER-Positive Localized Breast Cancer — Dr Kalinsky

  • Major findings from the Phase III RxPONDER trial evaluating the role of chemotherapy for ER-positive, HER2-negative breast cancer with 1 to 3 positive lymph nodes and a 21-gene Recurrence Score® (RS) of ≤25
  • Other recent studies informing the use of the 21-gene RS to guide neoadjuvant and adjuvant treatment decision-making
  • Optimal selection, timing of initiation and duration of adjuvant endocrine therapy for ER-positive breast cancer; current clinical role of ovarian function suppression (OFS)/ablation for premenopausal women
  • Utility of OFS as a means to preserve fertility and/or prevent chemotherapy-associated premature ovarian insufficiency among premenopausal patients
  • Key efficacy and safety outcomes observed with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer at high risk for recurrence in the Phase III monarchE trial
  • Current guideline-endorsed indications for adjuvant abemaciclib; identification of appropriate candidates for this strategy
  • Emerging results from the Phase III NATALEE trial evaluating ribociclib as adjuvant therapy for ER-positive, HER2-negative breast cancer
  • Findings with olaparib as adjuvant therapy for ER-positive breast cancer with BRCA mutations in the Phase III OlympiA study; current role of adjuvant olaparib for this patient population

MODULE 3: Considerations in the Care of Patients with ER-Positive mBC — Dr Jhaveri

  • Long-term follow-up, including overall survival data, from pivotal clinical trials of palbociclib, ribociclib and abemaciclib for premenopausal and postmenopausal patients; factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner for first-line treatment
  • Available and emerging data sets (eg, from the RIGHT Choice, MAINTAIN, PACE, PALMIRA and SONIA trials) attempting to further define the optimal use of CDK4/6 inhibitors for ER-positive mBC
  • Efficacy and safety results from the Phase III EMERALD trial evaluating the oral selective estrogen receptor degrader (SERD) elacestrant for patients with ER-positive mBC after disease progression on CDK4/6 inhibitor-based therapy
  • Optimal integration of elacestrant into the current management of ER-positive mBC; importance of ESR1 mutation testing
  • Incidence and clinicopathologic characteristics of ER-positive, HER2-low mBC; rationale for the clinical activity of T-DXd in patients with HER2-low disease
  • Key findings from the Phase III DESTINY-Breast04 trial leading to the recent FDA approval of T-DXd for previously treated, HER2-low mBC; optimal sequencing for ER-positive disease
  • Key data from the Phase III TROPiCS-02 trial evaluating sacituzumab govitecan for ER-positive, HER2-negative mBC; FDA approval and current role of sacituzumab govitecan for this patient population
  • Current role of PARP inhibitors for ER-positive mBC with germline BRCA mutations
  • Rationale for and available data with circulating tumor DNA (ctDNA) testing to monitor for recurrence in patients with localized breast cancer; potential clinical impact of earlier detection of relapse

MODULE 4: Novel and Emerging Strategies for ER-Positive mBC — Dr Rugo

  • Biological rationale for the investigation of AKT inhibition in breast cancer; mechanism of action of capivasertib
  • Key efficacy and safety data from the Phase III CAPItello-291 study evaluating capivasertib/fulvestrant versus placebo/fulvestrant for recurrent ER-positive, HER2-negative mBC
  • Structural and mechanistic similarities and differences between investigational oral SERDs under development (eg, camizestrant, imlunestrant) and elacestrant
  • Efficacy and safety results from the Phase II SERENA-2 study of camizestrant compared to fulvestrant for postmenopausal women with advanced ER-positive, HER2-negative breast cancer
  • Available data with other oral SERDs; ongoing Phase III studies evaluating oral SERDs alone and in combination with other systemic therapies for ER-positive mBC
  • Early data with novel investigational antibody-drug conjugates, such as datopotamab deruxtecan and patritumab deruxtecan, for ER-positive mBC
  • Other novel agents and strategies under investigation for ER-positive mBC

MODULE 5: Evolving Clinical Decision-Making for Localized Triple-Negative Breast Cancer (TNBC) — Dr O’Shaughnessy

  • Recommended approaches to biomarker assessment for localized TNBC
  • Clinical and biological rationale for the investigation of immune checkpoint blockade and PARP inhibition for localized TNBC
  • Available data from the Phase III KEYNOTE-522 study of neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk, localized TNBC
  • Selection of appropriate candidates for and practical implementation of (neo)adjuvant pembrolizumab
  • Overall survival advantage and other key efficacy and safety findings observed with adjuvant olaparib in the Phase III OlympiA trial for high-risk, germline BRCA mutation-positive, HER2-negative breast cancer; implications for genetic testing and clinical management of localized TNBC
  • Available data with and ongoing clinical research studies evaluating other PARP inhibitors or immune checkpoint inhibitors as a component of neoadjuvant or adjuvant therapy for TNBC
  • Available data with and ongoing evaluation of ctDNA monitoring during and after neoadjuvant therapy as a means to better stratify risk and potentially inform further clinical decision-making
  • Other novel agents and strategies under investigation for localized TNBC

MODULE 6: Recent Advances in the Treatment of Metastatic TNBC (mTNBC) — Prof Schmid

  • Efficacy and safety findings with pembrolizumab/chemotherapy for previously untreated, PD-L1-positive mTNBC; optimal integration into practice
  • Published data evaluating the utility of ctDNA testing to assess immunotherapy response in patients with mTNBC; potential role of this strategy
  • Key clinical research findings guiding the use of PARP inhibitors for mTNBC
  • Available findings with and current role of PARP inhibitor monotherapy for patients with mBC harboring germline or somatic mutations in DNA damage response pathway genes beyond germline BRCA1/2
  • Outcomes reported with T-DXd among patients with ER-negative, HER2-low mBC in the DESTINY-Breast04 study; optimal sequencing of T-DXd opposite other available treatment options
  • Key efficacy and safety findings from the Phase III ASCENT trial comparing sacituzumab govitecan to physician’s choice of chemotherapy for relapsed/refractory mTNBC; integration into current clinical practice
  • Available efficacy and safety findings with and ongoing investigation of other antibody-drug conjugates, including datopotamab deruxtecan and patritumab deruxtecan, for mTNBC
  • Other novel agents and strategies under investigation for advanced TNBC

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate published research data to guide the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize adjuvant systemic therapy for newly diagnosed ER-positive breast cancer.
  • Consider available and emerging clinical trial findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the role of these agents as adjuvant treatment.
  • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, incorporating existing and recently approved anti-HER2 therapies.
  • Individualize the selection and sequencing of systemic therapy for ER-positive metastatic breast cancer, considering the patient’s age, menopausal status, prior treatment course, PIK3CA and ESR1 mutation status and level of HER2 expression.
  • Evaluate published research guiding the selection and sequencing of therapies for patients with localized and metastatic triple-negative breast cancer.
  • Appraise published efficacy and safety data with PARP inhibitors for patients with localized or metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
  • Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and strategies under development for localized and metastatic breast cancer.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr JhaveriConsultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc; Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. Dr KalinskyAdvisory Committee: 4D Pharma PLC, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Silicon Biosystems, Merck, Mersana Therapeutics Inc, Myovant Sciences, Novartis, OncoSec Medical, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Lilly, Novartis; Data and Safety Monitoring Board/Committee: Merck. Dr KropConsulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Seagen Inc; Contracted Research: Genentech, a member of the Roche Group, MacroGenics Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Merck, Novartis. Dr O’ShaughnessyAdvisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, GSK, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Ontada, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Synthon, Theralink, Veru; Nonrelevant Financial Relationship: prIME Oncology. Dr RugoConsultancy/Advisory Support: Blueprint Medicines, Napo Pharmaceuticals Inc, Puma Biotechnology Inc; Contracted Research: Ambrx, Astellas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Sermonix Pharmaceuticals, Taiho Oncology Inc, Veru Inc; Travel Support to Academic Meetings: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Merck. Prof SchmidConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Medivation Inc, a Pfizer Company, Novartis, OncoGenex Pharmaceuticals Inc, Roche Laboratories Inc.

CONTRIBUTING CLINICAL INVESTIGATORSSara A Hurvitz, MDContracted Research: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celcuity, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Dignitana AB, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, GSK, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Orinove Inc, Orum Therapeutics, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Zymeworks Inc; Nonrelevant Financial Relationship: Ideal Implant (spouse). Sara M Tolaney, MD, MPHConsulting Agreements: 4D Pharma PLC, Aadi Bioscience, ARC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Lilly, Menarini Group, Merck, Myovant Sciences, Novartis, OncoSec Medical, OncXerna Therapeutics Inc, Pfizer Inc, Reveal Genomics, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Umoja Biopharma, Zentalis Pharmaceuticals, Zetagen, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer Inc, Sanofi, Seagen Inc. Tiffany A Traina, MD, FASCOConsulting or Advisory Role: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, G1 Therapeutics Inc, GE Healthcare, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Hengrui Therapeutics Inc, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc, TerSera Therapeutics LLC; Research Funding (to Institution): Astellas, AstraZeneca Pharmaceuticals LP, Ayala Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Lilly, Merck, Natera Inc, Puma Biotechnology Inc, Seagen Inc, Stemline Therapeutics Inc, and TerSera Therapeutics LLC.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, general and breast surgeons and other healthcare providers involved in the treatment of breast cancer.

​ ​
IN-PERSON registration
Thank you for your interest in our CME program taking place in Chicago, IL. At this time online in-person preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:30 PM Central Time on Monday, June 5. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2023 ASCO Annual Meeting website. Please note: onsite registration does not guarantee meal service which will be based on availability.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.